Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19

• Main Authors: Wen-Hsiang Chen (Author), Peter J. Hotez (Author), Maria Elena Bottazzi (Author)
• פורמט: ספר
• יצא לאור: Taylor & Francis Group, 2020-06-01T00:00:00Z.
• נושאים: article
• גישה מקוונת: Connect to this object online.

A SARS-CoV receptor-binding domain (RBD) recombinant protein was developed and manufactured under current good manufacturing practices in 2016. The protein, known as RBD219-N1 when formulated on Alhydrogel®, induced high-level neutralizing antibodies and protective immunity with minimal immunopathol...